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1. INTRODUCTION. ISOLATION, AND STRUCTURAL
TYPES
Breviones are a new family of secondary metabolites that were
originally isolated from the New Zealand endemic fungus
Penicillium brevicompactum var. Dierckx.1,2 These compounds
are generally characterized by a new carbon skeleton, which we
have named breviane, that has three possible structural
variations: breviane, abeo-breviane, and abeo-norbreviane
(Figure 1). However, brevianes are not the only meroterpe-
noids with a terpene moiety linked to an α-pyrone ring.
Meroditerpenes, oxalicines, and decaturins also show a similar
structure. Sesquiterpenic meroterpenoids, pyripyropenes, and
arisugacins respond to the same pattern. All of these
compounds are of interest, not only because of their unusual
backbones but also because of the biological activities they have
shown. Hence, we had an interest in reviewing and presenting
all together the literature published on these compounds to
give an overall view of the state of the art on their chemistry.
This review covers the literature published on meroterpenes
with a breviane-like skeleton up to December 2012. It describes
the compounds isolated from natural sources, their biogenesis
and bioactivity, and the methods used to synthesize them.
Special attention has been paid to structure−activity relation-
ship studies (SAR) in section 4.4.
Brevianes present a basic diterpenic tricyclic core (rings A, B,
and C) that is mevalonic in origin and is similar to that of
perhydrophenanthrene. The core bears four methyl groups at
positions C4, C8, C10, and C13 and has defined stereo-
chemistry at positions C5, C8, C9, C10, and C14 (Figure 1).
The C1′−C7′ side chain has been proposed to have a
polyketide biosynthetic origin and is joined to the diterpenic
moiety through carbons C2′−C15′. The cyclization and
lactonization of this part of the molecule leads to the
characteristic breviane spiranic ring fused to the α-pyrone
(rings D and E, Figure 2). The main distinctive feature of 3(4→
18)-abeo-brevianes is the expansion of ring A to a cycloheptene
ring, a change that modifies the methyl group at C18. Finally, in
3(4→18)-abeo-1′-norbrevianes, the methyl group at C1′ is
lost―usually modified as a carbonyl group―and the α-
pyrone ring is expanded to an oxepane ring. The numbering
presented here is consistent with this mixed biogenetic
hypothesis and is the system used in all the latest papers on
the isolation and synthesis of brevianes and related compounds.
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Figure 1. Basic breviane skeletons.
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Breviones were originally described as a family of compounds
by the group of Macias et al.,1,2 who reported breviones A−E
(1−4 and 7). Recently, the discovery of breviones F−H (5, 6,
8) and I−K (9−11) from a Penicillium species (MCCC
3A00005) isolated from West Pacific deep sea marine
sediments,3,4 has been added to this family. Finally, the
Figure 2. Breviones and related compounds isolated from fungi and higher plants.
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decaturins A−D (12−15) were isolated from Penicillium
decaturense and Penicillium thiersii.5,6 The most distinctive
feature of decaturins is the presence of a pyridine ring attached
to the α-pyrone moiety, and in three examples (decaturins A−
C, 12−14) the carbonyl and the C20 methyl groups are also
modified as a hemiketal bridge. Despite the fact that these
compounds lack the two methyl groups at the α-pyrone ring,
they should be considered as brevianes and not as norbrevianes,
as discussed later in the section related to their possible
biogenetic pathways (Figure 2).
From nonfungal sources, one compound with the breviane
skeleton, named lygodinolide (16), has been described from
the fern Lygodium flexuosum.7 Other brevianes, named stypols
(17−19, 21), have been isolated from the tropical brown alga
Stypopodium zonale (Lamouroux) Papenfuss8,9 and, more
recently, from the brown alga Taonia atomaria10 (Figure 2).
More recently, the unusual compounds stypotriolal (20) and
stypohydroperoxide (22) were isolated from the brown alga
Stypopodium flabelliforme, along with the known compounds
stypoldione (21) and epistypodiol (18).11 These compounds
are brevianes by virtue of the number of carbons on the side
chain, but the α-pyrone ring has been replaced by a benzene or
an o-quinone ring.
A family of compounds named oxalicines (23−26) has been
isolated from P. thiersii. These have a structure similar to that of
breviones, but ring A has been cleaved and the methyl group
C20 has been modified to render a spirolactone ring at C10.
These compounds also present the typical spiranic ring fused to
the α-pyrone and an additional pyridine ring as a substituent in
the pyrone ring, as in the case of decaturins.5,6,12
Finally, pyripyropenes A−R (27−44), obtained from
Aspergillus fumigatus,13,14 and arisugacins (45−52), obtained
from Penicillium sp. FO-4259,15 are potent cholesterol
acyltransferase (ACAT) and acetylcholinesterase (AChE)
inhibitors, respectively.16 Instead of the typical diterpenic
moiety, these compounds contain a sesquiterpene unit linked
to a pyrone ring, which in turn is adorned with a nicotinate
(pyripyropenes) or benzene (arisugacins) subunit, and both
sets of compounds lack the oxygenated spirocenter typical of
breviones. Compactin (53) (Figure 3), obtained from P.
brevicompactum, is another example of a sesquiterpene linked to
a β-hydroxylated-γ-lactone ring17 and this system could render
the pyrone ring upon dehydrogenation.
2. BIOACTIVITY
Brevianes are of interest not only because of their structural
features but also because of their bioactivity and possible
ecological roles, yet the relatively recent discovery of these
compounds has not allowed a high number of studies on this
subject. However, the examples that have been reported are
very promising in terms of their possible uses.
The extract of the fern Lygodium flexuosum is known in
Indian folk medicine as a potent abortive.18 Strong postcoital
antifertility activity has been reported in rats and mice for the
EtOH and EtOH/water (7:3) extracts and also for the EtOH/
water extract in rabbits.18 However, attempts to use the pure
compound lygodinolide (16) have not been reported to date.
Breviones C (3) and E (7) have shown phytotoxic activity on
etiolated wheat coleoptiles,2 but other results regarding their
possible phytotoxic or fungicidal activities have not been
reported.
Decaturins have been reported to be strongly insecticidal. In
particular, decaturins B (13) and D (15) and oxalicines A (23)
and B (24) showed potent antiinsectan activity against
Spodoptera frugiperda, with dramatic reductions in the growth
rate observed when it was tested at a dietary level of 100 ppm.6
Some stypols (17−19, 21) showed potent deleterious effects
against the herbivorous fish Eupomucentrus leucostictus, with
stypotriol (19) and stypoldione (21) being especially toxic.
While not toxic, stypodiol (17) induces intense hyperactivity. It
has been suggested that this effect is partly responsible for the
“escape” behavior observed in fishes under controlled aquarium
conditions.9 Stypoldione (21) effectively inhibits synchronous
cell division in fertilized sea urchin (Strongylocentrus purpuratus
Stimpson) eggs with an ED50 of 1.1 μg/mL.
10 This compound
appears to act by inhibiting tubulin polymerization, thus
making it a promising candidate as an anticancer drug. In
addition, stypodiol (17) and stypoldione (21) show remarkable
antioxidant properties through radical-scavenging activity in
addition to structurally related (non-spiro-containing) mixed
meroditerpenoids taondiol (54) and iso-epi-taoindiol (55)
(Figure 3).10
Stypotriolal (20) showed moderate neurotoxic activity
against the mouse neuro-2a cell line, while stypotriolal and
stypohydroperoxide (22) caused modulation of intracellular
Ca2+ in rat cerebellar granule neurons (CGN).11 The biphasic
curve shown by 20 is consistent with action on a ligand-gated
or voltage-gated ion channel. Stypoldione (21) also proved to
Figure 3. Related meroterpenes, precursor, and micophenolic acid.
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be slightly active toward CGN and the suggested mode of
action is not associated with sodium channels.11
Despite the variety of biological activities shown by breviones
and structurally related compounds, their relatively recent
isolation has precluded in-depth studies on their ecological role,
the main requisites needed for the bioactivity or their possible
use as drugs. Recently, some structure−activity relationship
(SAR) studies have been performed on the diterpenic moiety,19
but further investigations are required. The relatively complex
nature of these compounds in comparison with their low
number of carbons, the high number of chiral centers, and the
high degree of functionalization make them attractive
candidates for such studies.
It seems reasonably clear that stypols play a defense role in
the algae from which they were isolated. However, the situation
is less clear in the case of the different Penicillium strains. The
deleterious effects shown by some breviones and decaturins
may indicate an active role as mycotoxins. However, the
presence of these compounds outside the producing organism
needs to be documented before such a function can be
unequivocally assigned. This is the case for the fern L.
flexuosum, for which only the deleterious effects of the extracts
have been reported,18 but the activity of the pure compound
lygodinolide (16) has not been described.
Regarding the possible medicinal activities of these
compounds, breviones F (5), G (6), and H (8) showed weak
inhibitory activity on the growth of HeLa cells and brevione F
(5) weakly inhibited replication of human immunodeficiency
virus type 1 (HIV-1).3
ACAT is a desirable target in drug design, as it catalyzes the
formation of cholesterol esters from cholesterol and fatty acids.
Thus, ACAT inhibitors have potential beneficial effects in
coronary atherosclerosis. Pyripyropenes have been reported as
potent ACAT inhibitors.20 Extensive QSAR studies with
pyripyropenes have resulted in the synthesis of more than
300 pyripyropene derivatives and the modeling of the
receptor’s cavity.14
Another important target is that related to arisugacins and
Alzheimer’s disease (AD). In this field, AChE has attracted
particular attention since the approval by the U.S. Food and
Drug Administration (FDA) of several AChE inhibitors for the
treatment of AD.21,22 In this respect, a survey of over 10 000
soil isolates containing actinomycetes and fungi led to the
isolation of arisugacins A (45) and B (46) from a Penicillium
spp. culture broth,23 and these were reported to be potent
AChE inhibitors.15,24 The discovery of arisugacins and
pyripyropenes illustrates the potency and importance of fungal
metabolites as a source of new drugs and also demonstrates the
possibilities of meroditerpenoids.
3. BIOGENETIC PATHWAY
The mixed biogenetic origin of breviones from mevalonate and
acetate pathways has been proposed by several authors2,9 and is
in good agreement with the biogenetic pathway proposed for
other meroterpenes such as pyripyropenes and arisugacins.
3.1. Sesquiterpenic Meroterpenoids. Pyripyropenes, and
Arisugacins
Metabolites of mixed origin are not unusual, but the
combination of a pyrone ring (acetate pathway in origin) and
a terpene is uncommon. The fungal metabolites pyripyropenes
and arisugacins are good examples of this combination of
features. These are two families of meroterpenoids that contain
a sesquiterpene unit instead of a diterpenic unit, as is the case
with breviones. As mentioned in section 1, pyripyropenes were
isolated from the fungus Aspergillus fumigatus, while arisugacins
Scheme 1. Biogenetic Pathway for Pyripyropenes and Arisugacins
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are Penicillium spp. metabolites. A similar biogenetic pathway
has been proposed for both families.
Feeding experiments using 13C-labeled acetate, mevalono-
lactone and nicotinic acid established the following biosynthetic
sequence for pyripyropenes: (1) condensation of two acetate
units with nicotinic acid leads to the pyridine-α-pyrone moiety
(A); (2) this moiety links to a pyrophosphate-farnesyl molecule
(B) that (3) undergoes epoxidation and trans-cyclization (C) as
for any other sesquiterpene molecule to render the basic
pyripyropene E (31).14 In the case of arisugacins (47−52), a
similar biogenetic pathway has been proposed with the
difference that a benzoic acid derivative and two acetate units
yield the benzyl-α-pyrone moiety (Scheme 1).25
3.2. Diterpenic Meroterpenoids: Breviones of Fungal
Origin
A similar combination of acetate and mevalonate pathways has
also been proposed for breviones.2,9 In this case, the
combination of three acetyl-CoA moieties and cyclization
renders the α,β,γ,δ-unsaturated lactone (Scheme 2). The
additional methyl group is delivered by methionine to yield
the final pyrone ring, a situation that was also proposed for
mycophenolic acid (MPA, 57) (Figure 3),26 another Penicillium
metabolite of mixed origin.
A mixed-origin metabolite arising from the addition of the α-
pyrone ring to one molecule of geranylgeranyl pyrophosphate
(GGP) should be placed at the beginning of the brevione
biosynthetic pathway in a similar way to that proposed for
pyripyropenes. This hypothesis is supported by the isolation of
2-geranylgeranyl-6-toluquinol (56) (Figure 3) from the alga
Stypopodium zonale.27 However, the isolation of a similar
metabolite with a pyrone ring (58) has not been reported to
date for any Penicillium or other fungus species. The cyclization
of such a metabolite would lead to the breviones (see section
3.3).
Either epoxidation followed by an all-trans geranylgeranyl-
cyclase enzymatic reaction or acid-catalyzed cyclization will lead
to the tricyclic diterpenic core of brevianes (breviones, stypols,
and decaturins). The advantage of the epoxidation pathway is
that the hydroxyl group at C3 is already introduced and only a
simple oxidation is needed to render the carbonyl group. The
acid-catalyzed mechanism is also feasible, but this requires a
harsh oxidation to render the same cyclohexanone ring A.
Isomerization of the double bond and epoxidation will allow
ring cyclization to give rise to the spirofuran ring D.
Dehydration of the alcohol will yield either brevione B (2) or
lygodinolide (16) (Scheme 2). Thus, brevione B (2) can be
considered as the source member of the brevione family in
fungi.
The 3-(4→18)-abeo-brevianes will arise due to cleavage of
the C3−C4 bond followed by rearrangement of the methyl
group C18 and dehydrogenation, thus rendering the expanded
Scheme 2. Biogenetic Hypothesis for Brevionesa
a(a) Allylic oxidation at ring C leads to breviones F (5) and G (6). (b) Oxidation at ring D is the key step leading to breviones D (4) and H (8) and
abeo-norbrevione E (7).
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brevione C (3). Subsequent oxidations at different positions
will lead to the other abeo-breviones. Finally, the only member
of the abeo-norbreviane family known to date could arise from
the ring opening, subsequent decarboxylation, and ring closing
etherification of the pyrone ring in brevione H (8) to render
brevione E (7).
Breviones are not the only meroterpenoids that have been
isolated from Penicillium spp. The isolation of compactin (53)17
(Figure 3) illustrates the fact that different linear terpenes (in
this case a sesquiterpene) may be assembled with a pyrone
moiety undergoing cyclization to render compactin (53) or
breviones, pyripyropenes, arisugacins, etc. In this case,
compactin has undergone cyclization but the lactone ring is
not dehydrogenated and the spiro ring is not present.
Finally, decaturins will respond to a similar biogenetic
pathway in which formation of the polyketide moiety will start
with the addition of two units of acetylcoenzyme A (AcCoA) to
a nicotinic acid molecule, as proposed for pyripyropenes
(Scheme 3). In this case, the delivery of a methyl group from
methionine is not necessary, in contrast to the case of
breviones.
3.3. Brevianes of Plant Origin
Investigations into the marine sea grass S. zonale led to the
isolation of stypols 17−20,8−11 which bear the typical brevione
backbone. The isolation from the same algae of 2-
geranylgeranyl-6-toluquinol (56)27 supports the biogenetic
hypothesis proposed previously for fungal breviones (Scheme
4). Moreover, linear meroditerpenes of this class with different
degrees of oxidation at the side chain and the aromatic ring
have been reported in many algae species.28
3.4. The Case of Oxalicines
In view of the structure of oxalicines, it is unlikely that
rearrangement of the pyrophosphate-geranyl precursor, oxida-
tion of the methyl group, and subsequent lactonization
necessary to change the tricyclic core ring structure would
take place at the beginning of the biosynthetic pathway. Rather,
decaturins A−C should be considered as the most likely
biogenetic precursors because they already contain the methyl
group modified as a hemiketal (decaturin C, 14). This
hemiketal group can readily undergo oxidative cleavage
between carbons C3 and C4, followed by lactonization, to
render oxalicines (Scheme 3). Consequently, decaturin C (14)
should be named as the precursor of 15-deoxyoxalicin A (26).
4. SYNTHESIS OF BREVIANES
The total synthesis of brevianes has been achieved and
published for breviones A−C (1−3), lygodinolide (16),
stypoldione (21), decaturins, arisugacins, and pyripyropenes.
Reviews on the synthesis and biological properties of breviones
(including stypoldiones),29 arisugacins, and pyripyropenes14,16
have been published. A route toward the formal synthesis of
abeo-brevianes has also been disclosed recently.30 However, a
review that addresses all of these materials together has not
been published to date. The approaches and retrosynthetic
analyses used in each case are different. However, a common
feature of all approaches is to split the molecule into the
diterpenic moiety and the pyrone ring (Scheme 5). As far as the
abeo-breviane skeleton is concerned, the two contributions on
the synthesis of this unit both involve the initial formation of
the breviane perhydrophenanthrene core but then use different
strategies to obtain the expanded cycloheptanone ring. The
Scheme 3. Biogenetic Pathway Proposed for Decaturins and Oxalicines
Scheme 4. Biogenetic Hypothesis for Stypols
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main differences concern the coupling between the diterpenic
unit and the aromatic moiety (α-pyrone, pyridyl-α-pyrone,
phenol, or o-quinone). The strategy selected by each author
determines the position of the double bonds in ring C and also
the protecting groups required. Accordingly, the methodologies
used to build up the pyrone ring and the tricyclic diterpenic
core (western half) will be discussed separately, as will the way
in which the two units are linked. Some comments on the
synthesis of the sesquiterpenic meroterpenoids, pyripyropenes,
and arisugacins will also be made.
4.1. Stypols and Breviones: Synthesis of the Western Half
The strategies used to build up the diterpenic half in breviones
and stypols are summarized in Table 1. The first synthesis of
racemic (±)-14-deoxystypoldione was reported by Mori and
Koga,31 and this was soon followed by the enantioselective
synthesis of (−)-stypoldione (21).32,33 The construction of ring
C in the enantioselective approach was achieved through the
SnCl4-catalyzed
34 ring closure in which the final stereo-
chemistry of the methyl group is governed by the angular
methyl group between rings A and B, which forces an α
orientation of the side chain (entry 1). However, the yield
obtained for this process was not very high (37%).
The synthesis of Falck et al.35 uses decaline 59 as starting
material (entry 2). The starting material was obtained from the
commercial triterpene 18β-glycyrrhetinic acid by Jones
oxidation and this compound comprises rings A and B. The
most remarkable aspect of the synthesis is the ring expansion
scheme followed to obtain ring C. To pursue this objective, a
transannular hydroboration from the less hindered α face of
decaline 59 followed by carbonylation of the resulting borane
gave the correct stereochemistry at the third angular methyl
group. A cyclopentenone was obtained, and treatment of this
compound with (phenylthiomethylidene)triphenylarsorane
(Ph3AsCHSPh) yielded a labile exocyclic epoxysulfide that
easily rearranged to the phenyl cyclohexanone thioether. This
compound was transformed into the α-phenylsulfoxide
hydrazine 60 depicted in Table 1 (entry 2), which was ready
to be incorporated into the aromatic ring (see section 4.3).
One of the advantages of the synthetic approach of Abad et
al.36 toward (−)-stypoldione (21) is that it uses the readily
available (+)-carvone (61) as the starting material for this
enantioselective synthetic design (entry 3). In this case, the
carbonyl group is protected as an OTBS-cyclopropane system.
Construction of the tricyclic core was achieved through thermal
ring-closing rearrangement of a triene precursor, a process that
gave rise to rings A and B with the correct orientation at all
stereocenters.
The novelty in the approach used by Xing and Demuth37 is
that it uses photoinduced free radical chemistry (entry 4).
Biomimetic light-induced radical cationic cyclization allowed
the tricyclic core of stypoldione (64) to be obtained
quantitatively in one impressive single step. Thus, starting
from geranylgeranyl acetate (63) and using catalytic amounts of
biphenyl and 1,4-dicyano-2,3,5,6-tetramethylbenzene
(TMDCB) as radical promoters, photoinduced electron
transfer (PET) yielded the corresponding acetylated tricyclic
moiety (64). It is noteworthy that the use of a protic solvent
probably induced the folding of the chain in the correct
conformation to obtain the desired stereochemistry at all chiral
centers.
Closely related to the previous biomimetic approach,
titanocene-catalyzed cyclization of epoxypolyenes was the
Scheme 5. Common Synthetic Plan Table 1. Synthetic Approaches to the Diterpenic Moiety of
Stypols, Breviones, and Decaturin D
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strategy selected by Justicia et al.38 in another example of step
economy (entry 5). The methodology represents an improve-
ment on previous procedures, in which stoichiometric amounts
of titanocene were needed.39 Treatment of the epoxypolyene
yields an unsaturated compound (66) that is closely related to
the one obtained by Xing and Demuth,37 but in this case 31%
overall yield was obtained.
Regarding breviones, there is a clear separation between the
perhydrophenanthrene-like and the expanded abeo-breviane
skeletons. In the former case, the common retrosynthetic
analysis includes a double Robinson annulation. Control of the
stereochemistry to render the Wieland−Mescher ketone uses a
typical approach with L-valine to obtain the correct orientation
of the methyl group that will end up as C-17 in the breviane
skeleton. However, major problems were encountered in the
second annulation, where racemization due to retro-aldolic
reactions occurred. This problem was solved in the first
instance using enzymatic resolution.
The first synthesis of brevione B was carried out in a racemic
form (entry 6),40 and this was soon followed by the first
enantioselective synthesis (entry 7), which employed an
enzymatic resolution of the retro-aldolic racemic mixture to
give 50% yield of the desired isomer (−)-D with 98.8%
enantiomeric excess (ee).41 Our own route toward the
synthesis of the western half of abeo-breviones overcame the
retro-aldolic reaction, which causes racemization by a single
change in the order of reactants, a situation that forced us to
carry out the annulation first (entry 8). Under these conditions
the base was not allowed to undergo the undesired retro-aldolic
reaction, thus enabling the first direct enantioselective synthesis
of synthon (+)-70 in one step fewer and with 80% ee (Scheme
6).19,30
The synthetic route of Takikawa takes the synthon (+)-73 to
the final epoxide (69), which is ready for the coupling with
synthon C through classical procedures involving Li/NH3
methylation, reduction, protection of the carbonyl group, and
oxidation to render 75 (Scheme 7).42 This compound is a key
point as it opens the route to 69, which incorporates all of the
required stereocenters and functional groups needed for the
coupling reaction (see section 4.3). This intermediate was also
used to carry out the first enantioselective synthesis of natural
(+)-decaturin D (15).42 Takikawa and co-workers43 have
recently carried out the first synthesis of decaturin C (14) using
the same methodology.
4.2. abeo-Breviones: Synthesis of the Western Half
Recently, the total synthesis of brevione C (3) has been
disclosed.44 Previously, only one approach to the synthesis of
expanded abeo-breviones had been published and this involved
a methodology based on a ring-expansion strategy using a
Lewis acid-catalyzed diazoalkane addition (Scheme 8).30 This
methodology has been previously shown to be useful to obtain
cycloheptanones from cyclohexanones.45 The reaction proceeds
via a Tiffeneau−Demjanov-type intermediate and Pd-catalyzed
oxidative dehydrosilylation of the TMS intermediate in a one-
pot experiment. Unexpectedly, the reaction was light-sensitive
and this allowed control over the regiochemistry of the
resulting double bond. The best yields and regioselectivity in
the desired isomer were obtained by carrying out the reaction
in the absence of light.
As can be observed, the regioselectivity of the reaction
changes markedly in the absence of light (Scheme 8, entry 2),
which for some reason favors homologation at the most
hindered carbon (pinacolinic cleavage b). When the reaction
was carried out in light, the type a pinacolinic cleavage prevailed
and the ratio between the two regioisomers was opposite to
that obtained in the dark. Previous reports on the influence of
light on this process have not been published. Also, under dark
conditions benzoquinone (BQ) cannot be excited to the triplet
state (3BQ) and direct Pd-catalyzed desilylation instead of β-
dehydrosilylation occurred to give the corresponding cyclo-
heptanone. Under light conditions, 3BQ reacted with the
palladium-silyl enol ether intermediate of the ring expansion
and the β-dehydrosilylation products were obtained.
Recently, Shishido and co-workers44 published the total
enantiocontrolled synthesis of breviones A−C (1−3). The
starting point was, as in other previous approaches, the optically
pure Wieland−Mescher ketone (Table 1, entry 9). However,
the authors’ choice in this case was a Baeyer−Villiger oxidation.
The corresponding lactone was subjected to ester cleavage and
reduction/oxidation (two steps) of the alkenyl methyl ester
yielded an alkenyl aldehyde. The 7-endo-trig-cyclization was
successfully achieved by use of tert-dodecanethiol and a radical
initiator [1,1′-azobis(cyclohexane-1-carbonitrile), V-40] to yield
the cycloheptenone depicted in Scheme 8 as a single product
and in good yield.
4.3. Sesquiterpenic Meroterpenoids: Synthesis of the
Western Half
Several excellent reviews have been published on the synthesis
of sesquiterpenic meroterpenoids arisugacins and pyripyro-
penes.14,16 However, recent data have not been reviewed and
we will briefly cover this information and the latest develop-
ments in this area.
In the case of the merosesquiterpenoid pyripyropene A, the
reported strategy again involved the (+)-Wieland−Mescher
Ketone (WMK, 76) as the starting point to yield the alcohol 77
that, after several steps including a Pd-catalyzed carbonylation
and classical chemistry, led to compound 78, which is ready for
incorporation of the pyridine-α-pyrone moiety (Scheme 9).
Scheme 6. Enantioselective Synthesis of Synthon (+)-73
Scheme 7. Synthesis of Natural (+)-Decaturin D (15)
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The synthesis of 78 was also carried out by Justicia et al.,46 who
used the titanocene-catalyzed cascade cyclization procedure
that was successfully used in their approach to stypoldione
(Table 1, entry 5).47 In this case, the use of Ti(III) allowed
synthon 80 to be obtained and Pd-catalyzed remote
functionalization of 81 led to 83, which is structurally close
to 78.
Other approaches involve biomimetic strategies such as that
used for the synthesis of pyripyropenes E and similar to that
previously discussed for stypoldione (Table 1, entry 4). In this
particular case, the sequence involves the synthesis of an
epoxide derivative of a geranyl-type precursor that bears the
desired nicotinoyl moiety (84) (Scheme 9).48 Lewis acid (BF3·
Et2O)-catalyzed biomimetic cyclization led to intermediate 85,
which―after another cyclization to the α-pyrone ring with
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and acetylatio-
n―afforded pyripyropene E directly.
The biomimetic approach has also been successfully used in
the formal synthesis of pyripyropene A (27) (Scheme 9) using
the same acidic conditions as for pyripyropene E (31).49 The
reaction yielded the final intermediate 83, which is ready for
coupling with the pyrone ring following the procedure of
Scheme 8. Strategies for Ring Expansion Leading to the abeo-Breviane Skeletona
a (a) Light-sensitive Tiffeneau−Demjanov ring expansion toward the western half of abeo-breviones (adapted from Macias et al.).30 (b) Endo-trig
cyclization of the alkenyl aldehyde (adapted from Yokoe et al.).44
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Sunazuka and co-workers (section 4.4, Scheme 10). In this case,
the authors were aware that allyl silanes bearing ester groups
are sufficiently nucleophilic to undergo epoxy-olefin cyclization
under acidic conditions.50
For the synthesis of arisugacins, the approach of Sunazuka et
al.51 is conceptually similar to their synthetic pathway to
pyripyropene A, but in this case α-ionone (89) was used as the
starting material to gain access to the hemiketal (90) (Scheme
10). The key synthon is an α,β-unsaturated aldehyde (91)
rather than the α,β-unsaturated carboxymethyl ester 83 and, of
course, the chemistry used to gain access to the synthon is
different. Sunazuka successfully carried out two different
approaches to the arisugacin framework, which in one case
bore an epoxide moiety at ring B.
On the other hand, two different approaches have been used
by Jung and Min52 to access the sesquiterpenic unit of
arisugacins through concerted intramolecular reactions. One
approach is based on an intramolecular Diels−Alder reaction
with furan (IMDAF), which was previously optimized for this
skeleton,53 and the other was based on the 6π-electrocyclization
of a triene followed by singlet oxygen cycloaddition. Both
methods provide a synthon similar to 91 but in a more
advanced oxidation step. However, the route involving
endoperoxide 97 was not ultimately explored at the coupling
stage. In contrast, synthon 103, arising from the 6π-electro-
cyclization/oxygen cycloaddition strategy, was successfully used
in the coupling steps with the α-pyrone ring, even though these
units were not ultimately incorporated into arisugacins.
4.4. Structure−Activity Relationship Studies with
Pyripyropenes
Pyripyropenes are among the best ACAT inhibitors found in
nature, and their activity is in the nanomolar range.54 In view of
the high ACAT activity shown by pyripyropenes, several
structure−activity relationship (SAR) studies with structural
analogues of pyripyropenes have been undertaken. The main
issue in these studies is to obtain enough starting material to
carry out the synthesis of as many derivatives as possible.
Usually, pyripyropene A was used as the starting material in
such studies, as it can be obtained in relatively large amounts by
culturing. Structural modifications have been made during the
course of several studies in an effort to study the influence of
side chains, the degree of oxidation at ring C, and the
importance of the type of aromatic rings attached to the pyrone
moiety. Furthermore, in some studies pyripyropenes have been
used as starting materials in approaches toward arisugacins and
arisugacin analogues.
(1) Upon using pyripyropene A as the starting material,
selective deacetylation with DBU led to a secondary, sterically
Scheme 9. Pyripyropene Synthesis
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unhindered alcohol. This alcohol was used to introduce
carboxylic esters in a homologous series from two to eight
carbons, plus palmitoleic and branched alkylic, alkenylic, and
benzoic esters.55,56 The highest activity was obtained for the
valeroyl ester, with the IC50 values following a parabolic curve
through the series of compounds. Even though these results are
in good agreement with Hansch’s model and show that these
modifications should not affect the intrinsic activity at the target
site, the authors did not comment on this particular issue.
Lipophilia seems to be the factor that governs the changes in
the activity in this series and one would expect a quantitative
SAR correlation between log P and the IC50 value.
(2) The selectivity of 96 semisynthetic derivatives prepared
from fungal pyripyropene A toward ACAT1 and ACAT2
isoenzymes was investigated in a cell-based assay with ACAT1-
and ACAT2-expressing CHO cells.57 Eighteen derivatives,
including PR-71 (7-O-isocaproyl derivative), showed much
more potent ACAT2 inhibition (IC50 6.0−62 nM) than
pyripyropene A (IC50 70 nM). Among the compounds tested,
however, natural pyripyropene A showed the highest selectivity
toward ACAT2, with a selectivity index (SI) of >1000, followed
by PR-71 (SI = 667).57
(3) A SAR study on the cytotoxicity of pyripyropene acyl
derivatives on drug-resistant cancer cell lines has been
published.58 A relationship between the ACAT and cytotoxic
activities was not found. However, several pyripyropene
derivatives exhibited enhanced cytotoxic activity against
vincristine- and adriamycin-resistant cell lines, with the benzoyl
derivative identified as being especially active. The degree of
oxidation at ring C also proved to be of great importance for
the cytotoxic activity, with the fully dehydrogenated system
being the most active, followed by acetylated and hydroxylated
ring types and, finally, the γ-pyrone ring (Figure 4).
(4) Substitution of the N atom at the pyridyl group resulted
in lower activity by more than 2 orders of magnitude. The same
effect was produced by a change in the position of the N atom,
replacement of the pyridyl with a benzene ring, or replacing the
O in the α-pyridine ring by a N. These results indicate that the
pyridine-pyrone moiety is essential for the activity.59
(5) An evaluation was carried out on 48 pyripyropene A
derivatives in which the two hydroxyl groups at ring A had been
modified as 1−11 cyclic acetals and the hydroxyl group at ring
C was either free, acetylated, or had a valeroyl side chain.60
These changes were made on the basis of previously obtained
results.55 Once again the results clearly show that when the
hydroxyl group at C-7 is free, the compounds remain inactive,
Scheme 10. Synthesis of Arisugacins
Figure 4. Increasing order of cytotoxic activity of pyripyropenes
depending on the degree of oxidation at ring C.
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regardless of the substituents in the hemiketal ring (substituted
aromatic rings, methyl, ethyl, isopropyl, tert-butyl, allyl), and
that the acetyl esters can be converted into ketals with retention
of the activity as long as the C7-OH group is esterified. It
Scheme 11. Coupling between Sesquiterpenic or Diterpenic Moiety and Pyrone Ring
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therefore seems that it is not only lipophilia that plays a role in
this series but also the presence of hydrophobic areas in certain
parts of the molecule that match with the active pocket of the
enzyme. Furthermore, the presence of a hydrophobic area in
the β face of the ring A and/or the ketal ring seems to be
important to improve the activity as the aromatic acetal
derivatives of substituted benzaldehydes are the most active
compounds.60
(6) Esterification of the four hydroxyl groups of pyripyr-
opene A led to the following types of esters (52 derivatives
tested in total):
(a) Pr, nBu, nVal, iBu at C1, C7, C11; C13 free, and all
hydroxyl groups free (4). The compound with all hydroxyl
groups free was almost inactive, whereas the triacyl derivatives
were at least 1 order of magnitude less active than pyripyropene
A.61
(b) Substitution with a longer acyl group at C11 (Ac, nPr,
nBu, nVal, iBu) or C-13 (Ac, Pr, nBu, iBu) while the other
hydroxyls are acetylated resulted in diminution of the activity.
Substituent at C-11 should not be bulky and C-13 hydroxl
group should be free.
(c) Substitution at the C-7 hydroxyl group is crucial for
the activity.
(7) Surprisingly, arisugacins and pyripyropenes are closely
structurally related compounds with totally different biological
activities. While pyripyropenes are acyl-CoA:cholesterol trans-
ferase (ACAT) inhibitors, arisugacins are acetylcholinesterase
(AChE) inhibitors. The main structural differences arise from
the aromatic ring substituent attached to the pyrone moiety
(pyridine in pyripyropenes, phenyl for arisugacins). While
pyripyropene A is available at gram scale, arisugacins can be
obtained only in small amounts. Thus, pyripyropene A was
converted into a mixed pyripyropene/arisugacin-like compound
by removing and replacing the pyridine ring by a substituted
phenyl or a different pyridyl ring. The new compounds did not
show significant AChE activity, with the exception of the 4-
pyridyl derivative, and marginal AChE activities were found for
“pyripyropenes” bearing an arisugacin-like phenyl ring. Despite
the low activities, it was shown that pyripyropenes can be
converted into AChE inhibitors.62
(8) Conversely, replacement of the pyridyl by an aryl group
in pyripyropene resulted in ca. 100-fold loss of the ACAT
activity, thus showing the importance of this moiety for the
activity.63
4.5. Coupling Strategies
Coupling between the sesquiterpenic or diterpenic moiety and
the pyrone ring is achieved through three main strategies that
involve metal-catalyzed or SN2 reactions (Scheme 11).
Metal-catalyzed strategies have been tried unsuccessfully with
palladium for breviones and decaturins,40−42 while the
palladium-catalyzed Stille coupling reaction of arylstannanes
has been used to achieve the synthesis of stypoldiones.32,33 A
strategy involving SN2′ nucleophilic additions to epoxides was
used by Takikawa et al.40,41 to access brevione B. Surprisingly,
the Pd(0)-catalyzed SN2′ coupling reaction worked well with
the simplified model compound, but steric demands led to
failure when the brevione precursor was treated under the same
conditions, with the reaction giving a β-enone at ring C as a
consequence of the hydride β-elimination of the π-allylpalla-
dium complex.41 The conversion was successfully achieved and
the reaction proceeded smoothly under thermal conditions
without addition of Pd(0) or Lewis acid or base, and the best
results were obtained with anisole as solvent. The same
procedure was successfully used to achieve the first
enantioselective synthesis of decaturin D.42 In both cases the
use of anisole as solvent gave the best yields, followed by
xylene. The use of solvents such as pyridine, diphenyl ether,
chlorobenzene, or nitrobenzene yielded only small amounts or
traces of the desired furospiranic compound, thus illustrating
the importance of solvent effects in this process.
On the other hand, strategies such as benzyllithium
nucleophilic additions to carbonyl groups have been used in
the synthesis of stypoldione.36,64 Similar strategies, but using
organocopper aryl complexes and an aldehyde, were used by
Xing and Demuth37 in the synthesis of stypoldione (21).
The use of SN2 reactions is well illustrated by Falck’s
approach to stypoldione (Scheme 11). In this case the enolate
was generated in the diterpenic half of the molecule and reacted
with the appropriate benzyl bromide derivative. Mild acidic
conditions (HI) led to removal of the sulfoxide moiety from the
hydrazine group and this was followed by intramolecular axial
attack of the nucleophilic oxygen in the aromatic ring to give
spiroketalization.35
Finally, the recently published synthesis of brevione C by
Shishido and co-workers44 addresses this question from a
different viewpoint (Scheme 11). In this case, the authors’ use
of oxidative radical coupling with ceric ammonium nitrate
(CAN) yielded the desired product in 65% yield as a separable
10:1 diastereomeric mixture. However, the best yields and
diastereoselectivities were obtained with a mixture of CAN and
Cu(AcO)2 and an ionic liquid ([bmim]BF4)/dichloromethane
(DCM) mixture.
The control of the stereochemical pathway toward
preparation of the correct enantiomer at the spiranic center
was not always totally successful, and a mixture of the two
enantiomers was often obtained.
Falck’s synthesis rendered only the natural enantiomer, and
the stereochemical pathway in this process is governed by the
methyl group located close to the benzyl moiety (Scheme 12),
which was also the case in Mori’s and Xing’s approaches to
stypoldione.
The approach of Abad et al.64 led to a mixture of
enantiomeric precursors of stypoldione and epi-stypoldione,
which in turn provided the corresponding target compounds
when treated under acidic conditions (Scheme 11). Finally, the
published syntheses of brevione B and decaturin D also led to
mixtures of the two enantiomers.
As can be seen, the strategies used for spirocyclization are not
particularly abundant, but this is also true for the synthetic
procedures published to date for meroditerpenes with a
furospiranic ring. More work is needed to open up new
enantioselective synthetic routes toward these interesting and
promising compounds.
Scheme 12. Stereoselective Spirocyclization to Stypoldiones
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Regarding the synthesis of the γ-pyrone ring in pyripyr-
openes, Sunazuka and co-workers65 envisaged a direct linkage
between the nicotin-hydroxy-α-pyrone subunit and the
sesquiterpenic moiety in trifluoroacetic or Lewis acid (AlCl3)
(Scheme 13). The mechanism is proposed to proceed through
an O-acylation, followed by in situ 1,3-acyl-migration and 1,4-
cyclization. This approach differs from that used later by the
same author to gain access to arisugacins.51 In this case a
Knoevenagel-type condensation was carried out between the
α,β-unsaturated aldehyde and the α-pyrone ring, which carried
the appropriate substituents in the aromatic ring, in the
presence of L-proline. Elimination of the proline moiety and
electrocyclic ring closure led to the appropriate precursor of
arisugacin A. However, epoxidation at the double bond failed
and no reaction occurred, a finding attributed to the steric
hindrance of the axial face neighboring α-hydroxyl and β-
methyl groups. Consequently, the authors changed the
stereochemistry of the hydroxyl group to β, and epoxidation
then took place. Reduction of the hydroxyl group in the
appropriate enantiomer by use of Et3SiH was followed by
functionalization at ring A to render arisugacin A. The same
strategy was used to obtain arisugacin E (Scheme 13).
Another strategy used to access arisugacin A involved an
indium-catalyzed coupling between a lactol and the pyrone
ring, which was thought to proceed via an oxocarbonium
intermediate.66 Unfortunately, all attempts to cleave the lactol
ring failed, and the synthesis of arisugacin A could not be
completed.
5. CONCLUSIONS
Meroterpenes are a family of compounds from mixed
biogenetic pathways and they have great potential as drug
leads. The biological activity of pyripyropenes and their
potential as ACAT and AChE inhibitors make their synthesis
attractive, and this also highlights the desirability of exploring
the potential of other members of the family such as breviones.
The complexity of these molecules and their synthesis has led
to the development of useful synthetic tools, especially for
coupling of the diterpenic and polyketide (pyrone) rings and
the spirocycle. From the biogenetic point of view, it seems that
sesquiterpenic and diterpenic meroterpenes could have similar
biogenetic pathways. Accordingly, both merosesquiterpenes
and meroditerpenes could be included in one single class of
natural products.
In summary, meroterpenes with a spirocycle and a pyrone
ring are attractive targets for synthesis and biological evaluation,
especially regarding their ACAT and AchE potential.
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